Foamix/PDUFA

Hi guys,

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology

• An NDA for FMX101 to treat acne vulgaris was filed with the FDA.
  
  • A PDUFA date has been established for October 20, 2019.
    
    Long:
    • LMT 1- 3.15$ (20 % of the planned investment amount)
      
      • LMT 2- 2.89$ (40 % of the planned investment amount)
        
        • LMT 3- 2.78$ (40 % of the planned investment amount)
          TP:7$
          
          
          Comments and likes are greatly appreciated.
          
          I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions and this is not a call for investment. I am not receiving compensation for it . I have no business relationship with any company whose stock is mentioned in this article.